Roche touts early trial success of second obesity drug candidate
Releads, adds shares in paragraph 3, background in paragraph 8
By Paolo Laudani and Ludwig Burger
July 17 (Reuters) -Roche ROG.S said on Wednesday a second drug candidate from its purchase of Carmot Therapeutics yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a late contender in the race to develop obesity drugs.
Roche's experimental once-daily pill CT-996 resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patients without diabetes in a Phase I trial, Roche said in a statement.
The stock jumped 6.7% at the open, a similar market reaction to positive trial results from another Carmot drug in May.
Roche is among a growing number of would-be rivals to Novo Nordisk NOVOb.CO and Eli Lilly LLY.N, whose weight-loss drugs have been in feverish demand, with experts boosting their sales forecasts for such treatments to as much as $150 billion by the early 2030s.
Roche's experimental pill, which could appeal to patients averse to injections,was well tolerated, with mostly mild or moderate gastrointestinal side effects similar to those seen in other weight-loss drugs,according to the statement.
"We are pleased to see the clinically meaningful weight loss in people treated with our oral GLP-1 therapy CT-996, which could eventually help patients address both chronic weight management and glycemic control indications," Roche's chief medical officer Levi Garraway said.
Based on the results in the first of three phases of testing on humans,CT-996 will advance to the second stage, Roche said.
Another drug candidate known as CT-388 from Roche's Carmot takeover, a self-administered once-weekly injection like Novo and Lilly's leading products, succeeded in a Phase I trial in May.
Roche in December agreed to take over Carmot for $2.7 billion upfront, joining other companies seeking to challenge the dominant makers of weight-loss drugs Novo and Lilly.
Reporting by Paolo Laudani, Editing by Rachel More, Sherry Jacob-Phillips and Bernadette Baum
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
